Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (6): 45-50.doi: 10.6040/j.issn.1671-7554.0.2021.0377
Previous Articles Next Articles
DU Jiaojiao1, ZHUANG Xianghua1, CHEN Shihong1, WANG Xuemeng2,3, JIANG Dongqing1, WU Fei1, HAN Xiaolin2, HUA Mengyu2, SONG Yuwen1
CLC Number:
[1] Akkawi I, Zmerly H. Osteoporosis: current concepts [J]. Joints, 2018, 6(2): 122-127. [2] De Martinis M, Sirufo MM, Ginaldi L. Osteoporosis: current and emerging therapies targeted to immunological checkpoints [J]. Curr Med Chem, 2020, 27(37): 6356-6372. [3] Ponzetti M, Rucci N. Updates on osteoimmunology: whats new on the cross-talk between bone and immune system [J]. Front Endocrinol(Lausanne), 2019, 10: 236. doi: 10.3389/fendo.2019.00236. [4] Catalan-Dibene J, Mcintyre LL, Zlotnik A. Interleukin 30 to interleukin 40 [J]. J Interferon Cytokine Res, 2018, 38(10): 423-439. [5] Ginaldi L, De Martinis M, Ciccarelli F, et al. Increased levels of interleukin 31(IL-31)in osteoporosis [J]. BMC Immunol, 2015, 16: 60. doi: 10.1186/s12865-015-0125-9. [6] Ginaldi L, De Martinis M, Saitta S, et al. Interleukin-33 serum levels in postmenopausal women with osteoporosis [J]. Sci Rep, 2019, 9(1): 3786. [7] Petra AI, Tsilioni I, Taracanova A, et al. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E [J]. Allergy Asthma Proc, 2018, 39(2): 153-160. [8] Cheung PF, Wong CK, Ho AW, et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis [J]. Int Immunol, 2010, 22(6): 453-467. [9] Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice [J]. Nat Immunol, 2004, 5(7): 752-760. [10] Dambacher J, Beigel F, Seiderer J, et al. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease [J]. Gut, 2007, 56(9): 1257-1265. [11] Lee CH, Hong CH, Yu WT, et al. Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis [J]. Br J Dermatol, 2012, 167(4): 794-803. [12] Chattopadhyay S, Tracy E, Liang P, et al. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells [J]. J Biol Chem, 2007, 282(5): 3014-3026. [13] Takayanagi H. Osteoimmunology in 2014: Two-faced immunology-from osteogenesis to bone resorption [J]. Nat Rev Rheumatol, 2015, 11(2): 74-76. [14] 夏维波,章振林,林华,等. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 25(3): 281-309. [15] Azizieh FY, Shehab D, Al JK, et al. Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD [J]. J Inflamm Res, 2019, 12: 99-108. doi: 10.2147/JIR.S203590. [16] Cop N, Ebo DG, Bridts CH, et al. Influence of IL-6, IL-33, and TNF-alpha on human mast cell activation: Lessons from single cell analysis by flow cytometry [J]. Cytometry B Clin Cytom, 2018, 94(3): 405-411. [17] Stott B, Lavender P, Lehmann S, et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation [J]. J Allergy Clin Immunol, 2013, 132(2): 446-454. [18] Schnittker D, Kwofie K, Ashkar A, et al. Oncostatin M and TLR-4 ligand synergize to induce MCP-1, IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells [J]. Mediators Inflamm, 2013, 2013: 317503. doi: 10.1155/2013/317503. [19] Rosine N, Etcheto A, Hendel-Chavez H, et al. Increase in Il-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis [J]. Sci Rep, 2018, 8(1): 7731. [20] Cornelissen C, Luscher-Firzlaff J, Baron JM, et al. Signaling by IL-31 and functional consequences [J]. Eur J Cell Biol, 2012, 91(6-7): 552-566. [21] Zhang Q, Putheti P, Zhou Q, et al. Structures and biological functions of IL-31 and IL-31 receptors [J]. Cytokine Growth Factor Rev, 2008, 19(5-6): 347-356. [22] Perrigoue JG, Li J, Zaph C, et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung [J]. J Exp Med, 2007, 204(3): 481-487. [23] De Martinis M, Franceschi C, Monti D, et al. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity [J]. FEBS Lett, 2005, 579(10): 2035-2039. [24] Zhao R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective [J]. Int J Med Sci, 2012, 9(9): 825-832. [25] Inada M, Miyaura C. Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis [J]. Clin Calcium, 2010, 20(10): 1467-1472. [26] Ginaldi L, De Martinis M. Osteoimmunology and Beyond [J]. Curr Med Chem, 2016, 23(33): 3754-3774. [27] Zoltowska NA, Lei Y, Adner M, et al. Mast cell-dependent IL-33/ST2 signaling is protective against the development of airway hyperresponsiveness in a house dust mite mouse model of asthma [J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314(3): 484-492. [28] Saidi S, Bouri F, Lencel P, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling [J]. Cytokine, 2011, 53(3): 347-354. [29] Schulze J, Bickert T, Beil FT, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells [J]. J Bone Miner Res, 2011, 26(4): 704-717. [30] Velickovic M, Pejnovic N, Mitrovic S, et al. ST2 deletion increases inflammatory bone destruction in experimentally induced periapical lesions in mice [J]. J Endod, 2015, 41(3): 369-375. [31] Zaiss MM, Kurowska-Stolarska M, Bohm C, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss [J]. J Immunol, 2011, 186(11): 6097-6105. [32] Taichman RS, Reilly MJ, Matthews LS. Human osteoblast-like cells and osteosarcoma cell lines synthesize macrophage inhibitory protein 1alpha in response to interleukin 1beta and tumour necrosis factor alpha stimulation in vitro [J]. Br J Haematol, 2000, 108(2): 275-283. [33] Da LF, Oliveira AP, Borges D, et al. The physiopathological role of IL-33: new highlights in bone biology and a proposed role in periodontal disease [J]. Mediators Inflamm, 2014, 2014: 342410. doi: 10.1155/2014/342410. [34] Saleh H, Eeles D, Hodge JM, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro [J]. Endocrinology, 2011, 152(5): 1911-1922. [35] Saluja R, Ketelaar ME, Hawro T, et al. The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders [J]. Mol Immunol, 2015, 63(1): 80-85. [36] Di Salvo E, Ventura-Spagnolo E, Casciaro M, et al. IL-33/IL-31 axis: a potential inflammatory pathway [J]. Mediators Inflamm, 2018, 2018: 3858032. doi: 10.1155/2018/3858032. [37] Brylka LJ, Schinke T. Chemokines in physiological and pathological bone remodeling [J]. Front Immunol, 2019, 10: 2182. doi: 10.3389/fimmu.2019.02182. |
[1] | KANG Chengwei, LIU Lei, PU Xiaobing, TAN Gang, DONG Changchao, YAN Zhaokui. Analysis of bone metabolism and bone turnover markers in 62 cases of osteoporosis with subclinical hypothyroidism [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 82-86. |
[2] | XU Daxia, HOU Nan, LI Xiaofeng, WANG Chuang, KONG Meng, JIAO Guangjun, CHEN Yunzhen. Relevance between bone metabolism of glucocorticoid-induced osteoporosis and duration of glucocorticoid treatment [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 103-107. |
[3] | ZHANG Jing, HAO Lanxiang, ZHANG Xiaochen, ZHANG Yonghong, FAN Shanshan, LIU Yan, JIANG Ling. Effects of bisphenol A on the bone mineral densities of vertebrate and femoral bone in rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 36-40. |
[4] | FENG Xiaoyu, ZHANG Hongmei, CHE Xuanqiang, KANG Donghong. Therapeutic effects of human osteoblast-stimulating factor on osteoporosis of ovariectomized rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 8-12. |
[5] | YU Lei, LI Zhen. Expression of interleukin-33 and its function in the serum of patients with cerebrovascular disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(4): 75-79. |
[6] | ZHANG Hong-mei1, WANG Yan2, KANG Dong-hong1, CAO Wei1, LIU Tao1, WANG Ping1. Bone mineral density of vertebra lumbalis and femur of adult men in Jinan city [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(4): 67-70. |
[7] |
CHENG Kai-hua1, ZHANG Li-xin2.
Therapy and effect of GnHRa on sex hormone and bone mineral density in patients with endometriosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 83-86. |
[8] | LIU Mei1, ZHANG Jun2, WANG Xu-xia3. Changes of the mineral density of the alveolar bone between T1DM and T2DM rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(9): 53-. |
[9] | ZHANG Lei,LI Mu,QI Lei,CAI Zhong-xu,LI Yu-hua,SUN Yuan-liang. AGEs in the pathogenesis of diabetic osteoporosis and the preventive mechanism of insulin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(11): 1148-1152. |
|